PreOmics GmbH and Biognosys AG Prevail in U.S. Patent Challenge US PTAB Revokes Sole Independent and Other Central Claims of U.S. Patent 11,435,360. SCHLIEREN, Switzerland& MUNICH---- PreOmics GmbH and Biognosys AG today announced a favorable outcome in an inter partes review proceeding IPR2024‑ 01473 before the U.S. Patent Trial and Appeal Board. The PTAB has revoked the central claims of U.S. Patent No. 11,435,360, which is...

#BRKR PreOmics GmbH and Biognosys AG Prevail in U.S. Patent Challenge

www.stocktitan.net/news/BRKR/pre-omics-gmb-...

Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI Bruker (Nasdaq: BRKR) BEST division announced two multi-year supply agreements with two global healthcare OEMs totaling approximately $500 million in expected future BEST revenues, with one agreement extending up to seven years. The expanded framework agreements cover delivery of Bruker’s high-performance niobium-titanium-copper composite superconductors for next-generation MRI magnets, primarily to production sites in the United States and United Kingdom. Bruker said its superconductors support novel helium-free MRI magnet architectures and meet demanding field stability and homogeneity requirements while leveraging manufacturing sites in Europe and the US.

#BRKR Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

www.stocktitan.net/news/BRKR/bruker-announc...

RI Research Instruments Announces Major Orders for Enabling Technology for the Gamma-Ray Source of the Extreme Light Infrastructure (ELI) RI Research Instruments (BRKR) announced approximately €35 million of orders to supply key components and enabling subsystems for the gamma-ray source at ELI-NP in Romania, with major deliveries expected in late 2026. The scope covers expansion of an existing linac, beam-guiding and focusing components, a linac upgrade to increase pulse rate by 200x, and an optical resonator that amplifies the laser by more than 900x developed with LICOS (TUM spin-out).The system will produce high-flux, monochromatic, energy-tunable gamma rays (1–20 MeV) via inverse Compton scattering to support advanced nuclear and fundamental research.

#BRKR RI Research Instruments Announces Major Orders for Enabling Technology for the Gamma-Ray Source of the Extreme Light Infrastructure (ELI)

www.stocktitan.net/news/BRKR/ri-research-in...

Bruker Announces Orders for High-Performance Magnetic Resonance Systems for Materials and Life-Science Research from Leading European Institutions Bruker (Nasdaq: BRKR) announced approximately $25 million of orders for high-performance magnetic resonance systems from three European research institutions, with revenue recognition expected over fiscal 2026 and 2027.Orders include a novel NMR relaxometry system for École Normale Supérieure (ENS-PSL) to complement a 900 MHz spectrometer, two 800 MHz and one 100 MHz systems plus an E580 EPR spectrometer for Max Planck Institute for Solid-State Research focused on battery materials, and an ultra-high field 1 GHz NMR system for Institut Européen de Chimie et Biologie (IECB) as Bordeaux’s flagship platform. Separately, a second 1.2 GHz NMR system was accepted at the University of Birmingham in Q4 2025.

#BRKR Bruker Announces Orders for High-Performance Magnetic Resonance Systems for Materials and Life-Science Research from Leading European Institutions

www.stocktitan.net/news/BRKR/bruker-announc...

#BRKR #BRKRP Indaba Capital Announces Sale of AST Revolution to Bruker

www.stocktitan.net/news/BRKR/indaba-capital...

Bruker Reports Third Quarter 2025 Financial Results Bruker Corporation today announced financial results for the three and nine months ended September 30, 2025.. For FY2026, our major cost-savings initiatives are progressing well towards the high end of our $100 to $120 million cost-down targets and are expected to deliver significant operating margin expansion and EPS growth in 2026.”.

#BRKR Bruker Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/BRKR/bruker-reports...

Bruker Announces Orders for NIH- and NSF-Funded NMR Systems from New York Structural Biology Center, University of Delaware and Northwestern University Bruker (Nasdaq: BRKR) announced three federally funded NMR system orders totaling approximately $10 million, placed by the New York Structural Biology Center, University of Delaware and Northwestern University on October 3, 2025. The NYSBC order is an NIH-funded 700 MHz Multifield NMR Relaxometry system—the first in North America—serving a 9-institution New York consortium and the national NIH center. Delaware ordered a NSF-funded 600 MHz DNP NMR to serve 25+ internal groups and 12 collaborators. Northwestern ordered an 800 MHz spectrometer supporting 15+ NIH-funded groups. Deliveries are expected in 2026.

#BRKR Bruker Announces Orders for NIH- and NSF-Funded NMR Systems from New York Structural Biology Center, University of Delaware and Northwestern University

www.stocktitan.net/news/BRKR/bruker-announc...

Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock Bruker Corporation (Nasdaq: BRKR) has announced the pricing of its public offering of $600 million of 6.375% Mandatory Convertible Preferred Stock, Series A. The offering includes 2.4 million shares at a liquidation preference of $250 per share, with a 30-day option for underwriters to purchase an additional $90 million.The preferred stock will automatically convert to common stock on September 1, 2028, with conversion rates between 6.9534 and 8.5179 shares of common stock per preferred share. Dividends will be paid quarterly at a 6.375% annual rate starting December 1, 2025. The company expects net proceeds of approximately $582 million, which will be used to repay various term loans and credit facilities.

#BRKR Bruker Announces Pricing of Public Offering of $600 Million of 6.375% Mandatory Convertible Preferred Stock

www.stocktitan.net/news/BRKR/bruker-announc...

Michael Burry and 4 other investors just bought this under-the-radar stock.

Q2 buys in Bruker $BRKR:

• Ken Griffin – $56M (+115%)
• Joel Greenblatt – $16.7M (+334%)
• Michael Burry – $9.6M (New)
• Jeremy Grantham – $3M (+20%)
• Jefferies – $2.2M (New)

#Stocks #Investing #BRKR

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ONDS, #OKE, #UMAC, #RCAT, #BRKR

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ONDS 9.7x
2. #OKE 5.3x
3. #UMAC 5.3x
4. #RCAT 4.7x
5. #BRKR 3.6x

#OptionFlow #OptionsTrading #Trading

Breaking News: ( NASDAQ: #BRKR ) Expected earnings - Bruker Corporation

Bruker (BRKR) Q2 Revenue Slips 0.4% | The Motley Fool

#BRKR #31edc165-f14c-4ec8-a3e7-fc7fb3a3f208 #data-news

Origin | Interest | Match

Bruker Announces Major $120M Cost-Cutting Initiative as Q2 Earnings Miss Expectations Bruker targets $120M annual savings by 2026 while launching new proteomics innovations. Q2 revenue at $797.4M amid market headwinds. See strategic roadmap.

#BRKR Bruker Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/BRKR/bruker-reports...

Bruker Q2 Earnings Show $798M Revenue as Biopharma Weakness, Academic Slowdown Impact Results Preliminary Q2 results reveal flat revenue growth, 7% organic decline amid market headwinds. Learn how academic and biopharma challenges affect outlook. See full analysis.

#BRKR Bruker Announces Second Quarter 2025 Preliminary Results, Plans to Hold Q2 Earnings Conference Call on August 4, 2025

www.stocktitan.net/news/BRKR/bruker-announc...

Bruker Secures Massive 27-System Order as AI Chip Demand Drives Advanced Packaging Growth Leading semiconductor manufacturer orders 27 Bruker metrology systems for AI chip production. Latest installation marks growing demand for advanced packaging technology. Learn more.

#BRKR Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands

www.stocktitan.net/news/BRKR/bruker-experie...

Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics Bruker Corporation (BRKR) has unveiled the timsUltra AIP mass spectrometer featuring the breakthrough Athena Ion Processor technology at the 73rd ASMS Conference. The new system delivers enhanced sensitivity with up to 35% more peptide and 20% more protein identifications for ultra-high sensitivity 4D-Proteomics. When combined with the Evosep Eno nLC system, it can identify over 5000 proteins at 250 pg sample size with 100 samples per day throughput, or 2000 proteins at 500 samples per day. The technology significantly advances research capabilities in single-cell proteomics, FNA tumor biopsies, immunopeptidomics, and metaproteomics, enabling detection of bacterial peptides at sub-picogram levels.

#BRKR Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics

www.stocktitan.net/news/BRKR/bruker-launche...

Bruker Revolutionizes Proteomics: New nanoLC System Achieves 50% Sensitivity Boost with Advanced Column Technology Discover Bruker's proteoElute nanoLC system with ceramic valves and PepSep Advanced columns delivering 20% more peptide identifications. See breakthrough specs.

#BRKR Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity

www.stocktitan.net/news/BRKR/bruker-unveils...

Revolutionary timsOmni Mass Spectrometer Transforms Protein Research and Drug Development New timsOmni system enables unprecedented protein analysis with multimodal capabilities. Discover how this breakthrough impacts disease research and biologics development.

#BRKR Bruker Launches Revolutionary timsOmniTM Mass Spectrometer

www.stocktitan.net/news/BRKR/bruker-launche...

Major Patent Battle Ends: Bruker and 10x Genomics Strike Global Deal to Protect Spatial Biology Innovation Global settlement ensures continued access to CosMx and GeoMx platforms for scientific research. Multiple patent disputes resolved across US, Germany, and EU. See impact.

#BRKR Bruker and 10x Genomics Reach Global Settlement of Patent Litigation

www.stocktitan.net/news/BRKR/bruker-and-10x...

Bruker Reports First Quarter 2025 Financial Results Bruker Corporation (BRKR) reported Q1 2025 financial results with revenues of $801.4 million, showing an 11.0% year-over-year increase. The company's Bruker Scientific Instruments (BSI) segment demonstrated strong performance with 5.1% organic revenue growth, while Q1 2025 GAAP diluted EPS was $0.11 and non-GAAP diluted EPS was $0.47, down 11.3% year-over-year.Due to academic market and tariff challenges, Bruker has revised its FY 2025 guidance, now expecting revenues between $3.48 to $3.55 billion (3.5% to 5.5% growth) and non-GAAP EPS of $2.40 to $2.48 (0% to 3% growth). The company plans to implement cost and pricing initiatives, along with supply network re-engineering, to mitigate more than half of the new headwinds in 2025.

#BRKR Bruker Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/BRKR/bruker-reports...

Bruker's Strategic Move: $15M Revenue Diagnostics Firm RECIPE Acquisition Boosts Testing Portfolio Strategic acquisition enhances Bruker's diagnostic testing capabilities with RECIPE's ClinMASS kits and new ClinDART platform, promising 95% cost reduction. Full analysis inside.

#BRKR Bruker Announces Majority Acquisition of RECIPE, a Leading Provider of Mass Spectrometry-based Diagnostic Assay Kits for Therapeutic Drug Monitoring

www.stocktitan.net/news/BRKR/bruker-announc...

Bruker Crushes Q1 Revenue Estimates: Double-Digit Growth Signals Strong Performance Bruker reports Q1 revenue of $795-800M, exceeding forecasts with 10% YoY growth. BSI segment shows solid growth despite BEST segment decline. Full analysis inside.

#BRKR Bruker Announces First Quarter 2025 Preliminary Revenue

www.stocktitan.net/news/BRKR/bruker-announc...

Is Bruker Corporation (BRKR) an Oversold Value Stock to Buy According to Hedge Funds? - Yahoo Finance Is Bruker Corporation (BRKR) an Oversold Value Stock to Buy According to Hedge Funds?  Yahoo Finance

Click Subscribe #BrukerCorporation #BRKR #ValueStocks #Investing #HedgeFunds

#Doge doesn’t seem to understand that delaying/cutting #NIH funding to Universities not only hurts Unis & American lives, but also wallstreet. Cutting NIH research will impact biotech company revenue & thus their stock.
#TMO #NYSE #BDX #ILMN #A #TMO #BIO #RVTY #WAT #QGEN #DHR #BRKR #MTD #CZMWY

Insider Buying Trends Amid Uncertainties Ahead Explore insider buying strategies amidst political chaos and market unpredictability. Gain insights into market movements.

Last week, Dr. Frank H. Laukien, CEO of #BrukerCorp, purchased 46,000 shares of $BRKR on Oct 30th. Insider buying like this often signals confidence in the company’s future. Always pays to watch the insiders! See more at https://bit.ly/41qJX4a #BRKR #InsiderBuying

Revolutionary Leap in Protein Analysis: How Bruker's New Tech Makes Single-Cell Studies 25% More Powerful New timsTOF Ultra 2 system delivers 20-25% better peptide identification, while AI-powered software suite transforms proteomics research capabilities with 10x performance gains.

#BRKR Bruker Advances Single-Cell Proteomics and Immunopeptidomics Performance; Unveils New Proteomics Software and Applications for Enhanced Biological Insights at US HUPO

www.stocktitan.net/news/BRKR/bruker-advance...

Bruker Earnings Smash Expectations: Q4 Revenue Hits Record $979.6M, Charts Ambitious Growth Path Bruker delivers 14.6% Q4 revenue growth, EPS up 8.6%. Company projects robust 2025 with 11-13% EPS growth forecast amid strategic expansion into high-growth markets.

#BRKR Bruker Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/BRKR/bruker-reports...

Bruker Hit With $31.6M Patent Verdict, U.S. Court Blocks GeoMx Product Sales in Patent Battle Delaware Court upholds damages against Bruker in NanoString patent case, impacting GeoMx product line. Company plans appeal while maintaining minimal revenue impact.

#BRKR Bruker Comments on Delaware District Court’s Post-Trial Ruling in Case Involving GeoMx Digital Spatial Profiler Products

www.stocktitan.net/news/BRKR/bruker-comment...